Literature DB >> 19922738

Update on partial response in depression.

Michael E Thase1.   

Abstract

Full symptomatic remission is the optimal outcome for patients with major depression. Unfortunately, antidepressant efficacy is limited to partial response for a significant minority of patients. Incomplete remission of depressive symptoms is associated with increased risk of relapse, decreased functioning in work and social settings, and increased risk of eventual suicide. Factors that increase the likelihood of incomplete remission include chronicity, severe symptomatology, and comorbid illnesses. Strategies to manage incomplete remission include "watchful waiting" (ie, continuing the original medication for another 4 to 8 weeks to see if complete remission will develop), switching antidepressants, or adding a second, adjunctive treatment (ie, either beginning psychotherapy or a second medication to augment the original antidepressant). Augmentation strategies may well prove to be the preferred strategy for improving response if tolerability is not an issue. Although studies on predictive factors have not yielded definitive results, clinicians in practice often select adjunctive agents that target patients' persistent symptoms. Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922738     DOI: 10.4088/JCP.8133su1c.01

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

Review 1.  An overview of mood disorders in the DSM-5.

Authors:  Jan Fawcett
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

2.  Emotional stimuli and motor conversion disorder.

Authors:  Valerie Voon; Christina Brezing; Cecile Gallea; Rezvan Ameli; Karin Roelofs; W Curt LaFrance; Mark Hallett
Journal:  Brain       Date:  2010-04-05       Impact factor: 13.501

3.  Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.

Authors:  Wael Shamseddeen; Gregory Clarke; Martin B Keller; Karen Dineen Wagner; Boris Birmaher; Graham J Emslie; Neal Ryan; Joan Rosenbaum Asarnow; Giovanna Porta; David A Brent
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-01-17       Impact factor: 2.576

Review 4.  Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders.

Authors:  Alvaro Morcuende; María Salud García-Gutiérrez; Simone Tambaro; Elena Nieto; Jorge Manzanares; Teresa Femenia
Journal:  Front Psychiatry       Date:  2022-04-15       Impact factor: 5.435

5.  The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

Authors:  Stuart A Montgomery; Lucilla Mansuy; Adam C Ruth; Dayong Li; Carl Gommoll
Journal:  Int Clin Psychopharmacol       Date:  2014-01       Impact factor: 1.659

Review 6.  The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

Authors:  Antonio Bruno; Paolo Morabito; Edoardo Spina; Maria Rosaria Muscatello
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models.

Authors:  Gregory A Ordway; Attila Szebeni; Liza J Hernandez; Jessica D Crawford; Katalin Szebeni; Michelle J Chandley; Katherine C Burgess; Corwin Miller; Erol Bakkalbasi; Russell W Brown
Journal:  Int J Neuropsychopharmacol       Date:  2017-12-01       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.